P/E ratio for Aeterna Zentaris (AEZS)
P/E ratio as of May 2024 (TTM): -1.83
According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.82833. At the end of 2022 the company had a P/E ratio of -0.6809.
P/E ratio history for Aeterna Zentaris from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.6809 | -85.17% |
| 2021 | -4.59 | 61.16% |
| 2020 | -2.85 | 9.59% |
| 2019 | -2.60 | -122.11% |
| 2018 | 11.8 | -643.15% |
| 2017 | -2.17 | 45.55% |
| 2016 | -1.49 | 1059.17% |
| 2015 | -0.1283 | -93.78% |
| 2014 | -2.06 | -134.59% |
| 2013 | 5.97 | -360.77% |
| 2012 | -2.29 | -55.16% |
| 2011 | -5.10 | 2.89% |
| 2010 | -4.96 | 157.26% |
| 2009 | -1.93 | 340.82% |
| 2008 | -0.4375 | -82.68% |
| 2007 | -2.53 | -129.9% |
| 2006 | 8.44 | -61.41% |
| 2005 | 21.9 | -134.73% |
| 2004 | -63.0 | 823.38% |
| 2003 | -6.82 | -20.16% |
| 2002 | -8.55 | -91.15% |
| 2001 | -96.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 27.4 | -1,600.01% | 🇨🇭 Switzerland |
 Sanofi SNY | 15.3 | -937.04% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 11.1 | -706.60% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -2.86 | 56.49% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 25.7 | -1,505.40% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.